BRPI0520686A2 - uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer - Google Patents
uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncerInfo
- Publication number
- BRPI0520686A2 BRPI0520686A2 BRPI0520686-3A BRPI0520686A BRPI0520686A2 BR PI0520686 A2 BRPI0520686 A2 BR PI0520686A2 BR PI0520686 A BRPI0520686 A BR PI0520686A BR PI0520686 A2 BRPI0520686 A2 BR PI0520686A2
- Authority
- BR
- Brazil
- Prior art keywords
- transcriptome
- radiotherapy
- modifying agents
- chemotherapy
- agents associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
USO DE AGENTES MODIFICANTES DE TRANSCRIPTOMA ASSOCIADO A QUIMIOTERAPIA OU RADIOTERAPIA CONTRA O CáNCER. A presente invenção se relaciona com o uso de agentes modificantes do transcriptoma com o objetivo de impedir as células malignas de realizar as alterações gênicas necessárias para desenvolver dano celular e sobreviver a quimioterapia ou radioterapia. Esta combinação de modificantes do transcriptoma serão agentes que inibem a maquinaria de metilação do DNA associado a uma substância que impessa as modificações pós-traducionais das histonas. Se apresenta um kit de tratamento que consiste na administração de uma dose efetiva de hidralazina associado a vaíproato de magnésio para coadjuvar com a radioterapia ou quimioterapia no tratamento de pacientes com câncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2005/000106 WO2007075077A1 (es) | 2005-11-16 | 2005-11-16 | Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0520686A2 true BRPI0520686A2 (pt) | 2009-05-19 |
Family
ID=38218257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0520686-3A BRPI0520686A2 (pt) | 2005-11-16 | 2005-11-16 | uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer |
Country Status (12)
Country | Link |
---|---|
US (1) | US9186339B2 (pt) |
EP (1) | EP1949898A1 (pt) |
JP (1) | JP2009519898A (pt) |
CN (1) | CN101355934A (pt) |
AR (1) | AR058192A1 (pt) |
AU (1) | AU2005339587B2 (pt) |
BR (1) | BRPI0520686A2 (pt) |
CA (1) | CA2630334C (pt) |
CR (1) | CR9979A (pt) |
PE (1) | PE20070722A1 (pt) |
UY (1) | UY29901A1 (pt) |
WO (1) | WO2007075077A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
US20130102556A1 (en) * | 2010-02-02 | 2013-04-25 | The Johns Hopkins University | Use of N1,N4-bis[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine Compounds in Combination with Epigenetic-Acting Pharmaceuticals for Enhanced Cancer Therapy |
WO2016089916A1 (en) * | 2014-12-02 | 2016-06-09 | Roger Williams Hospital | Methods and compositons for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300373B1 (en) * | 1993-09-10 | 2001-10-09 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
US6713043B2 (en) * | 1996-02-29 | 2004-03-30 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil |
EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
WO2004006842A2 (en) * | 2002-07-11 | 2004-01-22 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
AU2003288263A1 (en) * | 2002-10-16 | 2004-05-04 | Pharmacia Italia S.P.A. | Use of substituted acrylolyl distamycin derivatives in combination with demethylating agents, in the treatment of cancer |
US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
PT1591109E (pt) * | 2004-04-30 | 2008-09-05 | Desitin Arzneimittel Gmbh | Formulação exibindo libertação bifásica compreendendo um inibidor da desacetilase de histona |
-
2005
- 2005-11-16 AU AU2005339587A patent/AU2005339587B2/en not_active Ceased
- 2005-11-16 WO PCT/MX2005/000106 patent/WO2007075077A1/es active Application Filing
- 2005-11-16 BR BRPI0520686-3A patent/BRPI0520686A2/pt not_active Application Discontinuation
- 2005-11-16 US US12/093,906 patent/US9186339B2/en active Active
- 2005-11-16 CA CA2630334A patent/CA2630334C/en active Active
- 2005-11-18 JP JP2008541095A patent/JP2009519898A/ja active Pending
- 2005-11-18 CN CNA2005800524947A patent/CN101355934A/zh active Pending
- 2005-11-18 EP EP05812723A patent/EP1949898A1/en not_active Withdrawn
-
2006
- 2006-11-06 UY UY29901A patent/UY29901A1/es not_active Application Discontinuation
- 2006-11-15 PE PE2006001453A patent/PE20070722A1/es not_active Application Discontinuation
- 2006-11-16 AR ARP060105030A patent/AR058192A1/es not_active Application Discontinuation
-
2008
- 2008-05-16 CR CR9979A patent/CR9979A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20090196851A1 (en) | 2009-08-06 |
UY29901A1 (es) | 2007-04-30 |
CA2630334A1 (en) | 2007-07-05 |
CA2630334C (en) | 2013-07-23 |
AU2005339587B2 (en) | 2011-11-03 |
US9186339B2 (en) | 2015-11-17 |
WO2007075077A8 (es) | 2008-11-20 |
AR058192A1 (es) | 2008-01-23 |
EP1949898A1 (en) | 2008-07-30 |
JP2009519898A (ja) | 2009-05-21 |
WO2007075077A1 (es) | 2007-07-05 |
CR9979A (es) | 2009-08-24 |
AU2005339587A1 (en) | 2007-07-05 |
AU2005339587A8 (en) | 2008-07-24 |
CN101355934A (zh) | 2009-01-28 |
PE20070722A1 (es) | 2007-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507039A8 (pt) | composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit | |
BR112019021822A2 (pt) | Terapia de combinação | |
BR112014030750A2 (pt) | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar | |
BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
BR112015008255A2 (pt) | método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata | |
BR112012020304A2 (pt) | complexo que alveja tecido, uso de um complexo que alveja tecido, método de tratamento de um corpo de animal humano ou não humano, composição farmacêutica, e, kit | |
WO2005116259A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
MX2010005081A (es) | Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco. | |
BR112013002298A2 (pt) | complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica. | |
WO2006133361A3 (en) | Use of gene expression profiling to predict survival in cancer patient | |
BR112012014569A8 (pt) | métodos e composições para destruição de tumores | |
BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
BR112015017490A2 (pt) | uso de nanopartículas inorgânicas | |
WO2010048144A3 (en) | Imaging and radiotherapy methods | |
GT201200275A (es) | Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores | |
Duan et al. | MicroRNA-145: a promising biomarker for hepatocellular carcinoma (HCC) | |
BRPI0520686A2 (pt) | uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer | |
HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
BR112012027463A2 (pt) | método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit | |
NO20064754L (no) | Kombinasjonsterapi | |
MX2020013883A (es) | Tratamientos oncológicos con agentes de zinc. | |
ECSP088454A (es) | Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer | |
WO2006055806A3 (en) | Diagnostic, prognostic, and therapeutic factor smac/diablo in human cancer | |
Ahmad et al. | Leukocyte superoxide dismutase activity in patients with chronic myeloid leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |